Isocaloric dietary changes and Non-Alcoholic fatty liver disease in high cardiometabolic risk individuals

Nutrients

Volumn 9, Issue 10, 2017, Pages

  Pepa, Giuseppe Della ^a   Vetrani, Claudia ^a   Lombardi, Gianluca ^a   Bozzetto, Lutgarda ^a   Annuzzi, Giovanni ^a   Rivellese, Angela Albarosa ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Carbohydrates; Isocaloric dietary changes; Monounsaturated fatty acids; NAFLD; NASH; Polyphenols; Polyunsaturated fatty acids; Vitamins

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBOHYDRATE; MONOUNSATURATED FATTY ACID; NUTRITION SUPPLEMENT; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; SATURATED FATTY ACID; TRACE ELEMENT; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

BODY MASS; CALORIC INTAKE; CALORIC RESTRICTION; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; ECHOGRAPHY; FAT INTAKE; GLUCOSE TRANSPORT; GLYCEMIC INDEX; HIGH FIBER DIET; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID STORAGE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LOW CALORY DIET; MEDITERRANEAN DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PHYSICAL ACTIVITY; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SKELETAL MUSCLE; WEIGHT REDUCTION; DIET THERAPY; DIETARY REFERENCE INTAKE; FEEDING BEHAVIOR; HABIT; HEALTHY DIET; LIPID METABOLISM; LIVER; METABOLISM; NUTRITIONAL VALUE; PATHOLOGY; PROGNOSIS; PROTECTION; RISK ASSESSMENT;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; ENERGY INTAKE; FEEDING BEHAVIOR; HABITS; HEALTHY DIET; HUMANS; LIPID METABOLISM; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; NUTRITIVE VALUE; OBESITY; PROGNOSIS; PROTECTIVE FACTORS; RECOMMENDED DIETARY ALLOWANCES; RISK ASSESSMENT; RISK FACTORS;

EID: 85030153167     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu9101065     Document Type: Review

References (180)

1. Haas, J.T., Francque, S., Stael, B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu. Rev. Physiol. 2016, 78, 181-205.
2. Francque, S.M., van der Graaff, D., Kwanten, W.J. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. J. Hepatol. 2016, 65, 425-443.
3. Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., Charlton, M., Sanyal, A.J. The Diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the study of liver diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55, 2005-2023.
4. Neuschwander-Tetri, B.A., Caldwell, S.H. Nonalcoholic steatohepatitis: Summary of an AASLD single topic conference. Hepatology 2003, 37, 1202-1219.
5. Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L., Wymer, M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016, 64, 73-84.
6. Yang, K.C., Hung, H.F., Lu, C.W., Chang, H.H., Lee, L.T., Huang, K.C. Association of non-alcoholic fatty liver disease with metabolic syndrome independently of central obesity and insulin resistance. Sci. Rep. 2016, 6, 27034.
7. Bozzetto, L., Annuzzi, G., Ragucci, M., Di Donato, O., Della Pepa, G., Della Corte, G., Griffo, E., Anniballi, G., Giacco, A., Mancini, M., et al. Insulin resistance, postprandial GLP-1 and adaptive immunity are the main predictors of NAFLD in a homogeneous population at high cardiovascular risk. Nutr. Metab. Cardiovasc. Dis. 2016, 26, 623-629.
8. López-Suárez, A., Guerrero, J.M., Elvira-Gonzáles, J., Beltrán-Robles, M., Cañas-Hormigo, F., Bascuñana-Quirell, A. Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase. Eur. J. Gastroenterol. Hepatol. 2011, 23, 1011-1017.
9. Blachier, M., Leleu, H., Peck-Radosavljevic, M., Valla, D.C., Roudot-Thoraval, F. The burden of liver disease in Europe: A review of available epidemiological data. J. Hepatol. 2013, 58, 593-608.
10. Yamazak, H., Tsuboya, T., Tsuji, K., Dohke, M., Maguchi, H. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes mellitus. Diabetes Care 2015, 38, 1673-1679.
11. Bush, H., Golabi, P., Younossi, Z.M. Pediatric non-alcoholic fatty liver disease. Children 2017, 4, 48.
12. Angulo, P. Long-term mortality in nonalcholic fatty liver disease: Is liver histology of any prognostic significance? Hepatology 2010, 51, 373-375.
13. Bellentani, S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017, 37, S81-S84.
14. Byrne, C.D., Targher, G. NAFLD: A multisystem disease. J. Hepatol. 2015, 62, S47-S64.
15. Bozzetto, L., Prinster, A., Mancini, M., Giacco, R., De Natale, C., Salvatore, M., Riccardi, G., Rivellese, A.A., Annuzzi, G. Liver fat in obesity: Role of type 2 diabetes mellitus and adipose tissue distribution. Eur. J. Clin. Investig. 2011, 41, 39-44.
16. Marcuccilli, M., Chonchol, M. NAFLD and chronic kidney disease. Int. J. Mol. Sci. 2016, 17, 562.
17. Day, C.P., James, O.F. Steatohepatitis: A tale of two “hits”? Gastroenterology 1998, 114, 842-845. [CrossRef]
18. Dowman, J.K., Tomlinson, J.W., Newsome, P.N. Pathogenesis of non-alcoholic fatty liver disease. Q. J. Med. 2010, 103, 71-83.
19. Donnelly, K.L., Smith, C.I., Schwarzenberg, S.J., Jessurun, J., Boldt, M.D., Parks, E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Investig. 2005, 115, 1343-1351.
20. Nguyen, P., Leray, V., Diez, M., Serisier, S., Le Bloc’h, J., Siliart, B., Dumon, H. Liver lipid metabolism. J. Anim. Physiol. Anim. Nutr. 2008, 92, 272-283.
21. Alam, S., Mustafa, G., Alam, M., Ahmad, N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J. Gastrointest. Pathophysiol. 2016, 7, 211-217.
22. Basaranoglu, M. From fatty liver to fibrosis: A tale of “second hit”. World J. Gastroenterol. 2013, 19, 1158-1165.
23. Tiniakos, D.G., Vos, M.B., Brunt, E.M. Nonalcoholic fatty liver disease: Pathology and pathogenesis. Annu. Rev. Pathol. 2010, 5, 145-171.
24. Buzzetti, E., Pinzani, M., Tsochatzis, E.A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016, 65, 1038-1048.
25. Kitade, H., Chen, G., Ni, Y., Ota, T. Nonalcoholic fatty liver disease and insulin resistance: New insights and potential new treatments. Nutrients 2017, 9, 387.
26. Mokhtari, Z., Gibson, D.L., Hekmatdoost, A. Nonalcoholic fatty liver disease, the gut microbiome, and diet. Adv. Nutr. 2017, 8, 240-252.
27. Sookoian, S., Pirola, C.J. Genetic predisposition in nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 2017, 23, 1-12.
28. Dongiovanni, P., Valenti, L. A Nutrigenomic approach to non-alcoholic fatty liver disease. Int. J. Mol. Sci. 2017, 18, 1534.
29. Naska, A., Trichopoulou, A. Nutrigenomics: The Genome-Food Interface. Environ. Health Perspect. 2007, 115, A582-A589.
30. Davis, J.N., Le, K.A., Walker, R.W., Vikman, S., Spruijt-Metz, D., Weigensberg, M.J., Allayee, H., Goran, M.I. Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption. Am. J. Clin. Nutr. 2010, 92, 1522-1527.
31. Anstee, Q.M., Day, C.P. The genetics of NAFLD. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 645-655.
32. Pirazzi, C., Adiels, M., Burza, M.A., Mancina, R.M., Levin, M., Ståhlman, M., Taskinen, M.R., Orho-Melander, M., Perman, J., Pujia, A., et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J. Hepatol. 2012, 57, 1276-1282.
33. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016, 64, 1388-1402.
34. Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., Tiribelli, C. The fatty liver index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006, 6, 33.
35. Kotronen, A., Peltonen, M., Hakkarainen, A., Sevastianova, K., Bergholm, R., Johansson, L.M., Lundbom, N., Rissanen, A., Ridderstråle, M., Groop, L., et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009, 137, 865-872.
36. Poynard, T., Lassailly, G., Diaz, E., Clement, K., Caïazzo, R., Tordjman, J., Munteanu, M., Perazzo, H., Demol, B., Callafe, R., et al. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: Meta-analysis of individual patient data. PLoS ONE 2012, 7, e30325.
37. Saadeh, S., Younossi, Z.M., Remer, E.M., Gramlich, T., Ong, J.P., Hurley, M., Mullen, K.D., Cooper, J.N., Sheridan, M.J. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002, 123, 745-750.
38. Mancini, M., Prinster, A., Annuzzi, G., Liuzzi, R., Giacco, R., Medagli, C., Cremone, M., Clemente, G., Maurea, S., Riccardi, G., et al. Sonographic hepatic-renal ratio as indicator of hepatic steatosis: Comparison with (1)H magnetic resonance spectroscopy. Metabolism 2009, 58, 1724-1730.
39. Guo, J., Friedman, S.L. Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. Fibrogenes. Tissue Repair 2010, 3, 21.
40. European Association for the Study of the Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J. Hepatol. 2015, 63, 237-264.
41. Wong, V.W., Vergniol, J.; Wong, G.L., Foucher, J., Chan, H.L., Le Bail, B., Choi, P.C., Kowo, M., Chan, A.W., Merrouche, W., et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010, 51, 454-462.
42. Toshimitsu, K., Matsuura, B., Ohkubo, I., Niiya, T., Furukawa, S., Hiasa, Y., Kawamura, M., Ebihara, K., Onji, M. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition 2007, 23, 46-52.
43. Naska, A., Trichopoulou, A. Back to the future: the Mediterranean diet paradigm. Nutr. Metab. Cardiovasc. Dis. 2014, 24, 216-219.
44. Romagnolo, D.F., Selmin, O.I. Mediterranean diet and prevention of chronic diseases. Nutr. Today 2017. [CrossRef]
45. Zelber-Sagi, S., Salomone, F., Mlynarsky, L. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms. Liver Int. 2017, 37, 936-949.
46. Allard, J.P., Aghdassi, E., Mohammed, S., Raman, M., Avand, G., Arendt, B.M., Jalali, P., Kandasamy, T., Prayitno, N., Sherman, M., et al. Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): A cross-sectional study. J. Hepatol. 2008, 48, 300-307.
47. Musso, G., Gambino, R., De Michieli, F., Cassader, M., Rizzetto, M., Durazzo, M., Fagà, E., Silli, B., Pagano, G. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003, 37, 909-916.
48. Westerbacka, J., Lammi, K., Häkkinen, A.M., Rissanen, A., Salminen, I., Aro, A., Yki-Järvinen, H. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J. Clin. Endocrinol. Metab. 2005, 90, 2804-2809.
49. Rosqvist, F., Iggman, D., Kullberg, J., Cedernaes, J., Johansson, H.E., Larsson, A., Johansson, L., Ahlström, H., Arner, P., Dahlman, I., et al. Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans. Diabetes 2014, 63, 2356-2368.
50. Cao, J., Dai, D.L., Yao, L., Yu, H.H., Ning, B., Zhang, Q., Cheng, W.H., Shen, W., Yang, Z.X. Saturated fatty acid induction of endoplasmic reticulum stress and apoptosis in human liver cells via the PERK/ATF4/CHOP signaling pathway. Mol. Cell. Biochem. 2012, 364, 115-129.
51. Lin, J., Yang, R., Tarr, P.T., Wu, P.H., Handschin, C., Li, S., Yang, W., Pei, L., Uldry, M., Tontonoz, P., et al. Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP. Cell 2005, 120, 261-273.
52. Leamy, A.K., Egnatchik, R.A., Young, J.D. Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog. Lipid Res. 2013, 52, 165-174.
53. Bozzetto, L., Prinster, A., Annuzzi, G., Costagliola, L., Mangione, A., Vitelli, A., Mazzarella, R., Longobardo, M., Mancini, M., Vigorito, C., et al. Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care 2012, 35, 1429-1435.
54. Ryan, M.C., Itsiopoulos, C., Thodis, T., Ward, G., Trost, N., Hofferberth, S., O’Dea, K., Desmond, P.V., Johnson, N.A.; Wilson, A.M. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J. Hepatol. 2013, 59, 138-143.
55. Nigam, P., Bhatt, S., Misra, A., Chadha, D.S., Vaidya, M., Dasgupta, J., Pasha, Q.M. Effect of a 6-month intervention with cooking oils containing a high concentration of monounsaturated fatty acids (olive and canola oils) compared with control oil in male Asian Indians with nonalcoholic fatty liver disease. Diabetes Technol. Ther. 2014, 16, 255-261.
56. Varela, L.M., Ortega-Gomez, A., Lopez, S., Abia, R., Muriana, F.J., Bermudez, B. The effects of dietary fatty acids on the postprandial triglyceride-rich lipoprotein/apoB48 receptor axis in human monocyte/macrophage cells. J. Nutr. Biochem. 2013, 24, 2031-2039.
57. DeLany, J.P.; Windhauser, M.M., Champagne, C.M., Bray, G.A. Differential oxidation of individual dietary fatty acids in humans. Am. J. Clin. Nutr. 2000, 72, 905-911.
58. Ferramosca, A., Savy, V., Zara, V. Olive oil increases the hepatic triacylglycerol content in mice by a distinct influence on the synthesis and oxidation of fatty acids. Biosci. Biotechnol. Biochem. 2008, 72, 62-69.
59. Bozzetto, L., Costabile, G., Luongo, D., Naviglio, D., Cicala, V., Piantadosi, C., Patti, L., Cipriano, P., Annuzzi, G., Rivellese, A.A. Reduction in liver fat by dietary MUFA in type 2 diabetes is helped by enhanced hepatic fat oxidation. Diabetologia 2016, 59, 2697-2701.
60. Hussein, O., Grosovski, M., Lasri, E., Svalb, S., Ravid, U., Assy, N. Monounsaturated fat decreases hepatic lipid content in non-alcoholic fatty liver disease in rats. World. J. Gastroenterol. 2007, 13, 361-368.
61. Rivellese, A.A., Giacco, R., Annuzzi, G., De Natale, C., Patti, L., Di Marino, L., Minerva, V., Costabile, G., Santangelo, C., Masella, R. Effects of monounsaturated vs. saturated fat on postprandial lipemia and adipose tissue lipases in type 2 diabetes. Clin. Nutr. 2008, 27, 133-141.
62. Zivkovic, A.M., German, J.B., Sanyal, A.J. Comparative review of diets for the metabolic syndrome: Implications for nonalcoholic fatty liver disease. Am. J. Clin. Nutr. 2007, 86, 285-300.
63. Juárez-Hernández, E., Chávez-Tapia, N.C., Uribe, M., Barbero-Becerra, V.J. Role of bioactive fatty acids in nonalcoholic fatty liver disease. Nutr. J. 2016, 15, 72.
64. Bjermo, H., Iggman, D., Kullberg, J., Dahlman, I., Johansson, L., Persson, L., Berglund, J., Pulkki, K., Basu, S., Uusitupa, M., et al. Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: A randomized controlled trial. Am. J. Clin. Nutr. 2012, 95, 1003-1012.
65. Nobili, V., Alisi, A., Musso, G., Scoreltti, E., Calder, P.C., Byrne, C.D. Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. Crit. Rev. Clin. Lab. Sci. 2016, 53, 106-120.
66. Spadaro, L., Magliocco, O., Spampinato, D., Piro, S., Oliveri, C., Alagona, C., Papa, G., Rabuazzo, A.M., Purrello, F. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig. Liver Dis. 2008, 40, 194-199.
67. Scorletti, E., Bhatia, L., McCormick, K.G., Clough, G.F., Nash, K., Hodson, L., Moyses, H.E., Calder, P.C., Byrne, C.D., WELCOME Study. Effects of purified eicosapentaenoic and docosahexaenoic acids in non-alcoholic fatty liver disease: Results from the WELCOME study. Hepatology 2014, 60, 1211-1221.
68. Zhu, F.S., Liu, S., Chen, X.M., Huang, Z.G., Zhang, D.W. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World. J. Gastroenterol. 2008, 14, 6395-6400.
69. Vega, G.L., Chandalia, M., Szczepaniak, L.S., Grundy, S.M. Effects of n-3 fatty acids on hepatic triglyceride content in humans. J. Investig. Med. 2008, 56, 780-785.
70. Argo, C.K., Patrie, J.T., Lackner, C., Henry, T.D., de Lange, E.E., Weltman, A.L., Shah, N.L., Al-Osaimi, A.M., Pramoonjago, P., Jayakumar, S., et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J. Hepatol. 2015, 62, 190-197.
71. Sanyal, A.J., Abdelmalek, M., Suzuki, A., Cummings, W., Chojkier, M. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 2014, 147, 377-384.
72. Cussons, J.A., Watts, G.F., Mori, T.A., Stuckey, B.G. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: A randomized controlled trial employing proton magnetic resonance spectroscopy. J. Clin. Endocrinol. Metab. 2009, 94, 3842-3848.
73. Schugar, R.C., Crawford, P.A. Low-carbohydrate ketogenic diets, glucose homeostasis, and nonalcoholic fatty liver disease. Curr. Opin. Clin. Nutr. Metab. Care 2012, 15, 374-380.
74. Da Silva-Santi, L.G., Masetto Antunes, M., Martins Caparroz-Assef, S., Carbonera, F., Nunes Masi, L., Curi, R., Visentainer, J.V., Barbosa Bazotte, R. Liver fatty acid composition and inflammation in mice fed with high-carbohydrate diet or high-fat diet. Nutrients 2016, 8, 682.
75. Valtuena, S., Pellegrini, N., Ardigo, D., Del Rio, D., Numeroso, F., Scazzina, F., Monti, L., Zavaroni, I., Brighenti, F. Dietary glycemic index and liver steatosis. Am. J. Clin. Nutr. 2006, 84, 136-142.
76. Moon, Y.A. The SCAP/SREBP pathway: A mediator of hepatic steatosis. Endocrinol. Metab. 2017, 32, 6-10.
77. Shirani, F., Zaribaf, F., Esmaillzadeh, A. Dietary glycemic index and glycemic load in relation to cardiovascular disease risk factors: A review of current evidence. J. Health Syst. Res. 2015, 10, 641-654.
78. Bawden, S., Stephenson, M., Falcone, Y., Lingaya, M., Ciampi, E., Hunter, K., Bligh, F., Schirra, J., Taylor, M., Morris, P., et al. Increased liver fat and glycogen stores after consumptionof high versus low glycaemic index food: A randomized crossover study. Diabetes Obes. Metab. 2017, 19, 70-77.
79. Rusul, E., Dragomir, A., Posea, M. Metabolic effects of low glycaemic index diets. Nutr. J. 2009, 8, 5.
80. Parnell, J.A., Reimer, A.R. Prebiotic fiber modulation of the gut microbiota improves risk factors for obesity and the metabolic syndrome. Gut Microbes 2012, 3, 29-34.
81. Utzschneider, K.M., Bayer-Carter, J.L., Arbuckle, M.D., Tidwell, J.M., Richards, T.L., Craft, S. Beneficial effect of a weight-stable, low-fat/low-saturated fat/low-glycaemic index diet to reduce liver fat in older subjects. Br. J. Nutr. 2013, 109, 1096-1104.
82. Misciagna, G., Del Pilar Díaz, M., Caramia, D.V., Bonfiglio, C., Franco, I., Noviello, M.R., Chiloiro, M., Abbrescia, D.I., Mirizzi, A., Tanzi, M., et al. Effect of a low glycemic index mediterranean diet on non-alcoholic fatty liver disease. A randomized controlled clinical trial. J. Nutr. Health Aging 2016, 21, 404-412.
83. Ramon-Krauel, M., Salsberg, S.L., Ebbeling, C.B., Voss, S., Mulkern, M.R., Cooke, E.A., Sarao, C., Jonas, M.M., Ludwig, D.S. Low-glycemic-load versus low-fat diet in the treatment of fatty liver in obese children. Child. Obes. 2013, 9, 252-260.
84. Fraser, A., Abel, R., Lawlor, D.A., Fraser, D., Elhayany, A. A modified Mediterranean diet is associated with the greatest reduction in alanine aminotransferase levels in obese type 2 diabetes patients: results of a quasi-randomised controlled trial. Diabetologia 2008, 51, 1616-1622.
85. Dhingra, D., Michael, M., Rajput, H., Patil, R.T. Dietary fibre in food: A review. J. Food Sci. Technol. 2012, 49, 255-266.
86. Cortez-Pinto, H., Jesus, L., Barros, H., Lopes, C., Moura, M.C., Camilo, M.E. How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin. Nutr. 2006, 25, 816-823.
87. Kim, C.H., Kallman, J.B., Bai, C., Pawloski, L., Gewa, C., Arsalla, A., Sabatella, M.E., Younossi, Z.M. Nutritional assessments of patients with non-alcoholic fatty liver disease. Obes. Surg. 2010, 20, 154-160.
88. Zolfaghari, H., Askari, G., Siassi, F., Feizi, A., Sotoudeh, G. Intake of nutrients, fiber, and sugar in patients with nonalcoholic fatty liver disease in comparison to healthy individuals. Int. J. Prev. Med. 2016, 7, 98.
89. Daubioul, C.A., Horsmans, Y., Lambert, P., Danse, E., Delzenne, N.M. Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: Results of a pilot study. Eur. J. Clin. Nutr. 2005, 59, 723-726.
90. Rippe, J.M., Angelopoulos, T.J. Fructose-containing sugars and cardiovascular disease. Adv. Nutr. 2015, 6, 430-439.
91. Nunes, P.M.; Wright, A.J., Veltien, A., van Asten, J.J., Tack, C.J., Jones, J.G., Heerschap, A. Dietary lipids do not contribute to the higher hepatic triglyceride levels of fructose-compared to glucose-fed mice. FASEB J. 2014, 28, 1988-1997.
92. Nseir, W., Nassar, F., Assy, N. Soft drinks consumption and nonalcoholic fatty liver disease. World J. Gastroenterol. 2010, 16, 2579-2588.
93. Abdelmalek, M.F., Suzuki, A., Guy, C., Unalp-Arida, A., Colvin, R., Johnson, R.J., Diehl, A.M. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010, 5, 1961-1971.
94. Ma, J., Fox, C.S., Jacques, P.F., Speliotes, E.K., Hoffmann, U., Smith, C.E., Saltzman, E., McKeown, N.M. Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts. J. Hepatol. 2015, 63, 462-469.
95. Dekker, M.J., Su, Q., Baker, C., Rutledge, A.C., Adeli, K. Fructose: A highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome. Am. J. Physiol. Endocrinol. Metab. 2010, 299, E685-E694.
96. Rebollo, A., Roglans, N., Alegret, M., Laguna, J.C. Way back for fructose and liver metabolism: Bench side to molecular insights. World J. Gastroenterol. 2012, 18, 6552-6559.
97. Basaranoglu, M., Basaranoglu, G., Bugianesi, E. Carbohydrate intake and nonalcoholic fatty liver disease: Fructose as a weapon of mass destruction. Hepatobiliary Surg. Nutr. 2015, 4, 109-116.
98. Bernardes, N., Ayyappan, P., De Angelis, K., Bagchi, A., Akolkar, G., da Silva Dias, D., Belló-Klein, A. Excessive consumption of fructose causes cardiometabolic dysfunctions through oxidative stress and inflammation. Can. J. Physiol. Pharmacol. 2017, 10, 1-13.
99. Mohamed, J., Nazratun Nafizah, A.H., Zariyantey, A.H., Budin, S.B. Mechanisms of diabetes-induced liver damage the role of oxidative stress and inflammation. Sult. Qaboos Univ. Med. J. 2016, 16, e132-e141.
100. Ngo Sock, E.T., Le, K.A., Ith, M., Kreis, R., Boesch, C., Tappy, L. Effects of a short-term overfeeding with fructose or glucose in healthy young males. Br. J. Nutr. 2010, 103, 939-943.
101. Silbernagel, G., Machann, J., Unmuth, S., Schick, F., Stefan, N., Haring, H.U., Fritsche, A. Effects of 4-week very-high-fructose/glucose diets on insulin sensitivity, visceral fat and intrahepatic lipids: An exploratory trial. Br. J. Nutr. 2011, 106, 79-86.
102. Maersk, M., Belza, A., Stodkilde-Jorgensen, H., Ringgaard, S., Chabanova, E., Thomsen, H., Pedersen, S.B., Astrup, A., Richelsen, B. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceralfat depot: A6-mo randomized intervention study. Am. J. Clin. Nutr. 2012, 95, 283-289.
103. Bravo, S., Lowndes, J., Sinnett, S., Yu, Z., Rippe, J. Consumption of sucrose and high-fructose corn syrup does not increase liver fat or ectopic fat deposition in muscles. Appl. Physiol. Nutr. Metab. 2013, 38, 681-688.
104. Lecoultre, V., Egli, L., Carrel, G., Theytaz, F., Kreis, R., Schneiter, P., Boss, A., Zwygart, K., Le, K.-A., Bortolotti, M. Effects of fructose and glucose overfeeding on hepatic insulin sensitivity and intrahepatic lipids in healthy humans. Obesity 2013, 21, 782-785.
105. Aeberli, I., Gerber, P.A., Hochuli, M., Kohler, S., Haile, S.R., Gouni-Berthold, I., Spinas, G.A., Berneis, K. Low to moderate sugar-sweetened beverage consumption impairs glucose and lipid metabolism and promotes inflammation in healthy young men: A randomized controlled trial. Am. J. Clin. Nutr. 2011, 94, 479-485.
106. Lê, K.A., Faeh, D., Stettler, R., Ith, M., Kreis, R., Vermathen, P., Boesch, C., Ravussin, E., Tappy, L. A 4-wk high-fructose diet alters lipid metabolism without affecting insulin sensitivity or ectopic lipids in healthy humans. Am. J. Clin. Nutr. 2006, 84, 1374-1379.
107. Taskinen, M.R., Söderlund, S., Bogl, L.H., Hakkarainen, A., Matikainen, N., Pietiläinen, K.H., Räsänen, S., Lundbom, N., Björnson, E., Eliasson, B., et al. Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity. J. Intern. Med. 2017, 282, 187-201.
108. Chiu, S., Sievenpiper, J.L., de Souza, R.J., Cozma, A.I., Mirrahimi, A., Carleton, A.J., Ha, V., Di Buono, M., Jenkins, A.L., Leiter, L.A., et al. Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of controlled feeding trials. Eur. J. Clin. Nutr. 2014, 68, 416-423.
109. Ma, J., Karlsen, M.C., Chung, M., Jacques, P.F., Saltzman, E., Smith, C.E., Fox, C.S., McKeown, N.M. Potential link between excess added sugar intake and ectopic fat: A systematic review of randomized controlled trials. Nutr. Rev. 2015, 74, 18-32.
110. Johnston, R.D., Stephenson, M.C., Crossland, H., Cordon, S.M., Palcidi, E., Cox, E.F., Taylor, M.A., Aithal, G.P., Macdonald, I.A. No difference between high-fructose and high-glucose diets on liver triacylglycerol or biochemistry in healthy overweight men. Gastroenterology 2013, 145, 1016-1025.
111. Pichon, L., Huneau, J.F., Fromentin, G., Tome, D. A high-protein, high-fat, carbohydrate-free diet reduces energy intake, hepatic lipogenesis, and adiposity in rats. J. Nutr. 2006, 136, 1256-1260.
112. Alferink, L., Kiefte-deJong, J.C.B., Schoufour, J.D., Taimr, P., Ikram, A.M., Janssen, H.L.A., Metselaar, H.J., Franco, O.H., Murad, S.D. Animal protein is the most important macronutrient associated with non-alcoholic fatty liver disease in overweight participants: The Rotterdam Study. J. Hepatol. 2017, 66, S50. [CrossRef]
113. Zelber-Sagi, S., Nitzan-Kaluski, D., Halpern, Z., Oren, R. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): A population based study. J. Hepatol. 2007, 47, 711-717.
114. Bortolotti, M., Maiolo, E., Corazza, M., Van Dijke, E., Schneiter, P., Boss, A., Carrel, G., Giusti, V., Lê, K.A., Chong, D.G.Q., et al. Effects of a whey protein supplementation on intrahepatocellular lipids in obese female patients. Clin. Nutr. 2011, 30, 494-498.
115. Duarte, S.M.B., Faintuch, J., Stefano, J.T., Oliveira, M.B.S.D., Mazo, D.F.D.C., Rabelo, F., Vanni, D., Nogueira, M.A., Carhillo, F.J., Oliveira, C.P.M.S.D. Hypocaloric high-protein diet improves clinical and biochemical markers in patients with nonalcoholic fatty liver disease (NAFLD). Nutr. Hosp. 2014, 29, 94-101.
116. Kani, A.H., Alavian, S.M., Esmaillzadeh, A., Adibi, P., Azadbakht, L. Effects of a novel therapeutic diet on liver enzymes and coagulating factors in patients with non-alcoholic fatty liver disease: A parallel randomized trial. Nutrition 2014, 30, 814-821.
117. Lima, G.P.P., Vianello, F., Corrêa, C.R., da Silva Campos, R.A., Borguini, M.G. Polyphenols in fruits and vegetables and its effect on human health. Food Nutr. Sci. 2014, 5, 1065-1082. [CrossRef]
118. Pérez-Jiménez, J., Fezeu, L., Touvier, M., Arnault, N., Manach, C., Hercberg, S., Galan, P., Scalbert, A. Dietary intake of 337 polyphenols in French adults. Am. J. Clin. Nutr. 2011, 93, 1220-1228.
119. Del Rio, D., Rodriguez-Mateos, A., Spencer, J.P., Tognolini, M., Borges, G., Crozier, A. Dietary (poly)phenolics in human health: Structures, bioavailability, and evidence of protective effects against chronic diseases. Antioxid. Redox Signal. 2013, 18, 1818-1892.
120. Annuzzi, G., Bozzetto, L., Costabile, G., Giacco, R., Mangione, A., Anniballi, G., Vitale, M., Vetrani, C., Cipriano, P., Della Corte, G., et al. Diets naturally rich in polyphenols improve fasting and postprandial dyslipidemia and reduce oxidative stress: a randomized controlled trial. Am. J. Clin. Nutr. 2014, 99, 463-471.
121. Salomone, F., Godos, J., Zelber-Sagi, S. Natural anti-oxidants for nonalcoholic fatty liver disease: Molecular targets and clinical perspectives. Liver Int. 2016, 36, 5-20.
122. Liu, J.F., Ma, Y.; Wang, Y., Du, Z., Shen, J.K., Peng, H.L. Reduction of lipid accumulation in HepG2 cells by luteolin is associated with activation of AMPK and mitigation of oxidative stress. Phytother. Res. 2011, 25, 588-596.
123. Chen, S., Zhao, X., Ran, L.; Wan, J.; Wang, X., Qin, J., Shu, F., Gao, Y., Yuan, L., Zhang, Q., et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial. Dig. Liver Dis. 2015, 47, 226-232.
124. Rodriguez-Ramiro, I., Vauzour, D., Minihane, A.M. Polyphenols and non-alcoholic fatty liver disease: Impact and mechanisms. Proc. Nutr. Soc. 2016, 75, 47-60.
125. Bozzetto, L., Annuzzi, G., Pacini, G., Costabile, G., Vetrani, C., Vitale, M., Griffo, E., Giacco, A., De Natale, C., Cocozza, S., et al. Polyphenol-rich diets improve glucose metabolism in people at high cardiometabolic risk: A controlled randomised intervention trial. Diabetologia 2015, 58, 1551-1560.
126. Shang, J., Chen, L.L., Xiao, F.X., Sun, H., Ding, H.C., Xiao, H. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol. Sin. 2008, 29, 698-706.
127. Chang, H.C., Peng, C.H., Yeh, D.M., Kao, E.S., Wang, C.J. Hibiscus sabdariffa extract inhibits obesity and fat accumulation, and improves liver steatosis in humans. Food Funct. 2014, 5, 734-739.
128. Guo, H., Zhong, R., Liu, Y., Jiang, X., Tang, X., Li, Z., Xia, M., Ling, W. Effects of bayberry juice on inflammatory and apoptotic markers in young adults with features of non-alcoholic fatty liver disease. Nutrition 2014, 30, 198-203.
129. Suda, I., Ishikawa, F., Hatakeyama, M., Miyawaki, M., Kudo, T., Hirano, K., Ito, A., Yamakawa, O., Horiuchi, S. Intake of purple sweet potato beverage affects on serum hepatic biomarker levels of healthy adult men with borderline hepatitis. Eur. J. Clin. Nutr. 2008, 62, 60-67.
130. Sakata, R., Nakamura, T., Torimura, T., Ueno, T., Sata, S. Green tea with high-density catechins improves liver function and fat infiltration in non alcoholic fatty liver disease (NAFLD) patients: A double-blind placebo-controlled study. Int. J. Mol. Med. 2013, 32, 989-994.
131. Poulsen, M.M., Vestergaard, P.F., Clasen, B.F., Radko, Y., Christensen, L.P., Stødkilde-Jørgensen, H., Møller, N., Jessen, N., Pedersen, S.B., Jørgensen, J.O.L. High-dose resveratrol supplementation in obese men: An investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013, 62, 1186-1195.
132. Heebøll, S., Kreuzfeldt, M., Hamilton-Dutoit, S., Poulsen, M.P., Stødkilde-Jørgensen, H., Møller, H.J., Jessen, N., Thorsen, K., Hellberg, Y.K., Pedersen, S.B., et al. Placebo-controlled, randomised clinical trial: high dose resveratrol treatment for non-alcoholic fatty liver disease. Scand. J. Gastroenterol. 2016, 51, 456-463.
133. Chachay, V.S., Macdonald, G.A., Martin, J.H., Whitehead, J.P., O’Moore-Sullivan, T.M., Lee, P., Franklin, M., Klein, K., Taylor, P.J., Ferguson, M., et al. Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease. Clin. Gastroenterol. Hepatol. 2014, 12, 2092-2103.
134. Faghihzadeh, F., Adibi, P., Rafiei, R., Hekmatdoost, A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr. Res. 2014, 34, 837-843.
135. Kwok, M.K., Leung, G.M., Schooling, C.M. Habitual coffee consumption and risk of type 2 diabetes, ischemic heart disease, depression and Alzheimer’s disease: A Mendelian randomization study. Sci. Rep. 2016, 6, 36500.
136. Wijarnpreecha, K., Thongprayoon, C., Ungprasert, P. Coffee consumption and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. Eur. J. Gastroenterol. Hepatol. 2017, 29, e8-e12.
137. Marventano, S., Salomone, F., Godos, J., Pluchinotta, F., Del Rio, D., Mistretta, A., Grosso, G. Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies. Clin. Nutr. 2016, 35, 1269-1281.
138. Shen, H., Rodriguez, A.C., Shiani, A., Lipka, S., Shahzad, G., Kumar, A., Mustacchia, P. Association between caffeine consumption and nonalcoholic fatty liver disease: A systemic review and meta-analysis. Ther. Adv. Gastroenterol. 2016, 9, 113-120.
139. Chen, S., Teoh, N.C., Chitturi, S., Farrell, G.C. Coffee and non-alcoholic fatty liver disease: Brewing evidence for hepatoprotection? J. Gastroenterol. Hepatol. 2014, 29, 435-441.
140. Vitaglione, P., Morisco, F., Mazzone, G., Amoruso, D.C., Ribecco, M.T., Romano, A., Fogliano, V., Caporaso, N., D’Argenio, G. Coffee reduces liver damage in a rat model of steatohepatitis: The underlying mechanisms and the role of polyphenols and melanoidins. Hepatology 2010, 52, 1652-1661.
141. Niki, E., Traber, M.G. A history of vitamin E. Ann. Nutr. Metab. 2012, 61, 207-212.
142. Traber, M.G. Vitamin E regulatory mechanisms. Annu. Rev. Nutr. 2007, 27, 347-362.
143. Rizvi, S., Raza, S.T., Ahmed, F., Ahmad, A., Abbas, S., Mahdi, F. The Role of Vitamin E in Human Health and Some Diseases. Sult. Qaboos Univ. Med. J. 2014, 14, e158-e165.
144. Nan, Y.M., Wu, W.J., Fu, N., Liang, B.L., Wang, R.Q., Li, L.X., Zhao, S.X., Zhao, J.M., Yu, J. Antioxidants vitamin E and 1-aminobenzotriazole prevent experimental non-alcoholic steatohepatitis in mice. Scand. J. Gastroenterol. 2009, 44, 1121-1131.
145. Phung, N., Pera, N., Farrell, G., Leclercq, I., Hou, J.Y., George, J. Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis. Int. J. Mol. Med. 2009, 24, 171-180.
146. Soden, J.S., Devereaux, M.W., Haas, J.E., Gumpricht, E., Dahl, R., Gralla, J., Traber, M.G., Sokol, R.J. Subcutaneous vitamin E ameliorates liver injury in an in vivo model of steatocholestasis. Hepatology 2007, 46, 485-495.
147. Hasegawa, T., Yoneda, M., Nakamura, K., Makino, I., Terano, A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: A pilot study. Aliment. Pharmacol. Ther. 2001, 15, 1667-1672.
148. Williams, D.B., Wan, Z., Frier, B.C., Bell, R.C., Field, C.J., Wright, D.C. Dietary supplementation with vitamin E and C attenuates dexamethasone-induced glucose intolerance in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012, 302, 49-58.
149. Sato, K., Gosho, M., Yamamoto, T., Kobayashi, Y., Ishii, N., Ohashi, T., Nakade, Y., Ito, K., Fukuzawa, Y., Yoneda, M. Vitamin E has a beneficial efficacy on nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Nutriton 2015, 31, 923-930.
150. Ji, H.F., Sun, Y., Shen, L. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH and CHC: Results from a meta-analysis. Nutrition 2014, 30, 986-991.
151. Sanyal, A.J., Chalasani, N., Kowdley, K.V., McCullough, A., Diehl, A.M., Bass, N.M., Neuschwander-Tetri, B.A., Lavine, J.E., Tonascia, J., Unalp, A., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J.Med. 2010, 362, 1675-1685.
152. Lavine, J.E., Schwimmer, J.B., Van Natta, M.L., Molleston, J.P., Murray, K.F., Rosenthal, P., Abrams, S.H., Scheimann, A.O., Sanyal, A.J., Chalasani, N., et al. Nonalcoholic steatohepatitis clinical research network. effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial. JAMA 2011, 305, 1659-1668.
153. Miller, E.R., Pastor-Barriuso, R., Dalal, D., Riemersma, R.A., Appel, L.J., Guallar, E. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 2005, 42, 37-46. [CrossRef]
154. Duarte, T.L., Lunec, J. Review: When is an antioxidant not an antioxidant? A review of novel actions and reactions of vitamin C. Free Radic. Res. 2005, 39, 671-686.
155. Naidu, K.A. Vitamin C in human health and disease is still a mystery? Nutr. J. 2003, 2, 7.
156. Lykkesfeldt, J., Poulsen, H.E. Is vitamin C supplementation beneficial? Lessons learned from randomized controlled trials. Br. J. Nutr. 2010, 103, 1251-1259.
157. Ferolla, S.M., Ferrari, T.C., Lima, M.L., Reis, T.O., Tavares, W.C., Jr., Couto, O.F., Vidigal, P.V., Fausto, M.A., Couto, C.A. Dietary patterns in brazilian patients with nonalcoholic fatty liver disease: A cross-sectional study. Clinics 2013, 68, 11-17. [CrossRef]
158. Canbakan, B., Senturk, H., Tahan, V., Hatemi, I., Balci, H., Toptas, T., Sonsuz, A., Velet, M., Aydin, S., Dirican, A., et al. Clinical, biochemical and histological correlations in a group of non-drinker subjects with non-alcoholic fatty liver disease. Acta Gastronterol. Belg. 2007, 70, 277-284.
159. Da Silva, H.E., Arendt, B.M., Noureldin, S.A., Therapondos, G., Guindi, M., Allard, J.P. A cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs. healthy controls. J. Acad. Nutr. Diet. 2014, 114, 1181-1194.
160. Madan, K., Bhardwaj, P., Thareja, S., Gupta, S.D., Saraya, A. Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD). J. Clin. Gastroenterol. 2006, 40, 930-935.
161. Mager, D.R., Patterson, C., So, S., Rogenstein, C.D.; Wykes, L.J., Roberts, E.A. Dietary and physical activity patterns in children with fatty liver. Eur. J. Clin. Nutr. 2010, 64, 628-635.
162. Valdecantos, M.P., Perez-Matute, P., Quintero, P., Martinez, J.A. Vitamin C, resveratrol and lipoic acid actions on isolated rat liver mitochondria: All antioxidants but different. Redox Rep. 2010, 15, 207-216.
163. Rose, F.J., Webster, J., Barry, J.B., Phillips, L.K., Richards, A.A., Whitehead, J.P. Synergistic effects of ascorbic acid and thiazolidinedione on secretion of high molecular weight adiponectin from human adipocytes. Diabetes Obes. Metab. 2010, 12, 1084-1089.
164. Harrison, S.A., Torgerson, S., Hayashi, P., Ward, J., Schenker, S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2003, 98, 2485-2490.
165. Nobili, V., Manco, M., Devito, R., di Ciommo, V., Comparcola, D., Sartorelli, M.R., Piemonte, F., Marcellini, M., Angulo, P. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial. Hepatology 2008, 48, 119-128.
166. Ersöz, G., Gunsar, F., Karasu, Z., Akay, S., Batur, Y., Akarca, U.S. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment. Turk. J. Gastroenterol. 2005, 16, 124-128.
167. Nobili, V., Manco, M., Devito, R., Ciampalini, P., Piemonte, F., Marcellini, M. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2006, 24, 1553-1561.
168. Cianferotti, L., Bertoldo, F., Bischoff-Ferrari, H.A., Bruyere, O., Cooper, C., Cutolo, M., Kanis, J.A., Kaufman, J.M., Reginster, J.Y., Rizzoli, R., et al. Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: Research for evidence and a scientific statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO). Endrocrine 2017, 56, 245-261.
169. Pittas, A.G., Chung, M., Trikalinos, T., Mitri, J., Brendel, M., Patel, K., Lichtenstein, A.H., Lau, J., Balk, E.M. Systematic review: Vitamin D and cardiometabolic outcomes. Ann. Intern. Med. 2010, 152, 307-314.
170. Barchetta, I., Angelico, F., Ben, M.D., Baroni, M.G., Pozzilli, P., Morini, S., Cavallo, M.G. Strong association between non-alcoholic fatty liver disease (NAFLD) and low 25 (OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med. 2011, 9, 85.
171. Annuzzi, G., Della Pepa, G., Vetrani, C. Vitamin D and cardiovascular disease: Is there evidence to support the bandwagon? Curr. Atheroscler. Rep. 2012, 14, 525-534.
172. Eliades, M., Spyrou, E., Agrawal, N., Lazo, M., Brancati, F.L., Potter, J.J., Koteish, A.A., Clark, J.M., Guallar, E., Hernaez, R. Meta-analysis: Vitamin D and non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2013, 38, 246-254.
173. Ning, C., Liu, L., Lv, G., Yang, Y., Zhang, Y., Yu, R.; Wang, Y., Zhu, J. Lipid metabolism and inflammation modulated by Vitamin D in liver of diabetic rats. Lipids Health Dis. 2015, 14, 31.
174. Shi, H., Norman, A.W., Okamura, W.H., Sen, A., Zemel, M.B. 1alpha, 25-Dihydroxyvitamin D3 modulates human adipocyte metabolism via nongenomic action. FASEB J. 2011, 15, 2751-2753.
175. Zhou, Q.G., Hou, F.F., Guo, Z.J., Liang, M.; Wang, G.B., Zhang, X. 1, 25-Dihydroxyvitamin D improved the free fatty-acid-induced insulin resistance in cultured C2C12 cells. Diabetes Metab. Res. Rev. 2004, 24, 459-464.
176. Nagpal, J., Pande, J.N., Bhartia, A. A double-blind randomized placebo controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet. Med. 2009, 26, 19-27.
177. Sharifi, N., Amani, R., Hajiani, E., Cheraghian, B. Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine 2014, 47, 70-80.
178. Barchetta, I., Del Ben, M., Angelico, F., Di Martino, M., Fraioli, A., La Torre, G., Saulle, R., Perri, L., Morini, S., Tiberti, C., et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. BMC Med. 2016, 14, 92.
179. Lorvand Amiri, H., Agah, S., Mousavi, S.N., Hosseini, A.F., Shidfar, F. Regression of non-alcoholic fatty liver by vitamin D supplement: A double-blind randomized controlled clinical trial. Arch. Iran. Med. 2016, 19, 631-638.
180. Gibson, P.S., Lang, S., Dhawan, A., Fitzpatrick, E., Blumfield, M.L., Truby, H., Hart, K.H., Moore, J.B. Systematic review: Nutrition and physical activity in the management of paediatric nonalcoholic fatty liver disease. J. Pediatr. Gastroenterol. Nutr. 2017, 65, 141-149.